Taken together, we speculate that CYP2E1/JNK is an essential therapeutic target for PM2.5-induced NAFLD and TF might be a natural product which could alleviate PM2.5-NAFLD associated hepatocyte damage via inhibiting CYP2E1/JNK. Here, MAPK8 is linked to metabolic dysfunction-associated steatotic liver disease.